Victory Capital Management Inc. Boosts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Victory Capital Management Inc. boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 198.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,833 shares of the medical equipment provider's stock after purchasing an additional 51,128 shares during the quarter. Victory Capital Management Inc. owned about 0.11% of Lantheus worth $8,432,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Signaturefd LLC raised its position in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 92 shares in the last quarter. GAMMA Investing LLC grew its position in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 208 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after acquiring an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in Lantheus during the 3rd quarter worth approximately $51,000. Finally, Nkcfo LLC acquired a new stake in Lantheus in the second quarter valued at approximately $47,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded up $3.20 during midday trading on Friday, reaching $90.52. The company's stock had a trading volume of 2,014,903 shares, compared to its average volume of 1,020,692. The firm has a 50 day moving average price of $103.43 and a two-hundred day moving average price of $96.53. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm has a market capitalization of $6.29 billion, a price-to-earnings ratio of 14.97 and a beta of 0.51.

Analyst Ratings Changes

LNTH has been the subject of a number of research reports. B. Riley increased their price target on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. JMP Securities reduced their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a report on Thursday, November 7th. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday. Finally, Truist Financial reaffirmed a "buy" rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.